Association of Cortical Gyrification With Imaging and Serum Biomarkers in Patients With Parkinson Disease

Yuanchao Zhang,Yu Zhang,Chengjie Mao,Zhen Jiang,Guohua Fan,Erlei Wang,Yifan Chen,Lena Palaniyappan

DOI: https://doi.org/10.1212/wnl.0000000000207410

IF: 9.9

2023-06-02

Neurology

Abstract:Background and Objectives Pathological progression across the cortex is a key feature of Parkinson disease (PD). Cortical gyrification is a morphologic feature of human cerebral cortex that is tightly linked to the integrity of underlying axonal connectivity. Monitoring cortical gyrification reductions may provide a sensitive marker of progression via structural connectivity, preceding the progressive stages of PD pathology. We aimed to examine the progressive cortical gyrification reductions and their associations with overlying cortical thickness, white matter (WM) integrity, striatum dopamine availability, serum neurofilament light (NfL) chain and cerebrospinal fluid (CSF) α-synuclein levels in PD. Methods This study included a longitudinal dataset with baseline (T0), 1-year (T1) and 4-year (T4) follow-ups, and two cross-sectional datasets. Local gyrification index (LGI) was computed from T1-weighted MRI data to measure cortical gyrification. Fractional anisotropy (FA) was computed from diffusion-weighted MRI data to measure WM integrity. Striatal binding ratio (SBR) was measured from 123 Ioflupane SPECT scans. Serum NfL and CSF α-synuclein levels were also measured. Results The longitudinal dataset included 113 de novo PD patients and 55 healthy controls (HC). The cross-sectional datasets included 116 patients with relatively more advanced PD and 85 HC. Compared with HC, de novo PD patients showed accelerated LGI and FA reductions over 1-year period and further decline at 4-year follow-up. Across the three time points, the LGI paralleled and correlated with FA (p=0.002 at T0, p=0.0214 at T1, p=0.0037 at T4) and SBR (p=0.0095 at T0, p=0.0035 at T1, p=0.0096 at T4) but not with overlying cortical thickness in PD patients. Both LGI and FA correlated with serum NfL level (LGI: p<0.0001 at T0, p=0.0043 at T1; FA: p<0.0001 at T0, p=0.0001 at T1) but not with CSF α-synuclein level in PD patients. In the two cross-sectional datasets, we revealed similar patterns of LGI and FA reductions and associations between LGI and FA in patients with more advanced PD. Discussion We demonstrated progressive reductions in cortical gyrification that were robustly associated with WM microstructure, striatum dopamine availability and serum NfL level in PD. Our findings may contribute biomarkers for PD progression and potential pathways for early interventions of PD.

clinical neurology